BeOne Medicines Ltd. - Sponsored ADR
BeOne Medicines Ltd. - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $5.3 billion, up 40.2% from fiscal 2024. In the quarter to June 2026, revenue grew 29.6%, EPS grew 143.7%, free cash flow grew 117.9% and total debt rose 503.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
Follow ONC
BeOne Medicines Ltd. - Sponsored ADR (ONC) Piotroski F-score
BeOne Medicines Ltd. - Sponsored ADR's Piotroski F-score for fiscal 2025 is 7 out of 9: 7 of nine tests of profitability, leverage and efficiency passed, up from 4 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 7 | 3.00 |
| FY2024 | 4 | 1.00 |
| FY2023 | 3 | 0.00 |
| FY2022 | 3 | (3.00) |
| FY2021 | 6 | 2.00 |
| FY2020 | 4 | 2.00 |
| FY2019 | 2 | (1.00) |
| FY2018 | 3 | (1.00) |
| FY2017 | 4 | 0.00 |
| FY2016 | 4 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | 4.07% | (11.00%) | Pass | 1 |
| Positive operating cash flow | 1.13b | (140.63m) | Pass | 1 |
| Rising return on assets | 4.07% | (11.00%) | Pass | 1 |
| Cash flow above net income | 840.65m | 504.16m | Pass | 1 |
| Falling long-term leverage | 0.14 | 0.03 | Fail | 0 |
| Rising current ratio | 3.41 | 1.80 | Pass | 1 |
| No new shares issued | 109,062,000 | 105,288,000 | Fail | 0 |
| Rising gross margin | 87.49% | 84.41% | Pass | 1 |
| Rising asset turnover | 0.76 | 0.65 | Pass | 1 |
| Piotroski F-score | Strong — most fundamentals improved | 7 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| INCY Incyte Corporation compare | 9 |
| ONC BeOne Medicines Ltd. - Sponsored ADR | 7 |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 6 |
| ARGX argenex SE compare | 5 |
| RPRX Royalty Pharma PLC compare | 5 |
| GMAB Genmab A/S Sponsored ADR compare | 4 |
| RVMD Revolution Medicines, Inc. compare | 4 |
| BNTX BioNTech SE Sponsored ADR compare | 4 |
| ROIV Roivant Sciences Ltd. compare | 2 |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover